Jacob J Adashek
Overview
Explore the profile of Jacob J Adashek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Paravathaneni M, Safa H, Joshi V, Tamil M, Adashek J, Ionescu F, et al.
EClinicalMedicine
. 2024 Jan;
68:102413.
PMID: 38273886
Background: Standardized, high-quality PRO data reporting is crucial for patient centered care in the field of oncology, especially in clinical trials that establish standard of care. This study evaluated PRO...
12.
Lim J, Kurzrock R, Nishizaki D, Miyashita H, Adashek J, Lee S, et al.
Cancer Med
. 2023 Dec;
13(1):e6844.
PMID: 38132831
Background: T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), an immune checkpoint receptor, dampens immune function. TIM-3 antagonists have entered the clinic. Methods: We analyzed TIM-3 transcriptomic expression in 514...
13.
Adashek J, Kato S, Sicklick J, Lippman S, Kurzrock R
Nat Cancer
. 2023 Dec;
4(12):1622-1626.
PMID: 38102355
No abstract available.
14.
Adashek J, Kurzrock R
NPJ Precis Oncol
. 2023 Dec;
7(1):129.
PMID: 38066094
In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for "mandatory" protocol visits/diagnostic testing. Studies suggest that the travel strain...
15.
Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek J
Pharmaceutics
. 2023 Aug;
15(8).
PMID: 37631374
Antibody-drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components-an antibody, a linker molecule, and a cytotoxic agent ("payload"), ADCs...
16.
Moeller A, Kurzrock R, Botta G, Adashek J, Patel H, Lee S, et al.
Am J Cancer Res
. 2023 Aug;
13(7):3257-3265.
PMID: 37560003
CSF1R expression modulates tumor-associated macrophages, making CSF1R blockade an appealing immune-modulating therapeutic target. We evaluated the correlation between CSF1R tumor RNA expression and outcome (pan-cancer setting). RNA expression was ranked...
17.
Shayeb A, Kurzrock R, Adashek J, Kato S
JCO Precis Oncol
. 2023 Jul;
7:e2200604.
PMID: 37437231
Purpose: Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low...
18.
Nelson B, Adashek J, Sheth A, Subbiah V
Mol Cancer Ther
. 2023 Jun;
22(6):706-716.
PMID: 37259805
Radiotherapy is a pillar of cancer treatment, which has historically been used primarily to treat localized disease with curative intent. With the increasing role of radiotherapy for metastatic disease and...
19.
Adashek J, Kato S, Nishizaki D, Miyashita H, De P, Lee S, et al.
Cancer Med
. 2023 May;
12(12):13155-13166.
PMID: 37132280
Background: Lymphocyte activation gene 3 (LAG-3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T-cell activation. Many clinical trials of LAG-3 inhibitors have had...
20.
Tateo V, Marchese P, Mollica V, Massari F, Kurzrock R, Adashek J
Pharmaceuticals (Basel)
. 2023 Apr;
16(4).
PMID: 37111371
(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments...